最新治疗方法推荐:英利昔单抗治疗溃疡性结肠炎

作     者：Das K.M. 赵丽娜 

作者机构：Crohn's/Colitis Ctr. of New Jersey Dept. of Gastroenterol. and Hepatol. Robert Wood Johnson Medical School 1 Robert Wood Johnson Place New Brunswick NJ 08901 United States Dr. 

出 版 物：《世界核心医学期刊文摘（胃肠病学分册）》 (Core Journals in Gastroenterology)

年 卷 期：2005年第1卷第2期

页      面：52-53页

学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

主　　题：溃疡性结肠炎 英利昔单抗 克罗恩病 难治性溃疡 抗肿瘤坏死因子 瘘管形成 其他疗法 嵌合抗体 皮质醇激素 

摘      要：Randomized, controlled studies have shown that infliximab, the chimeric anti- tumor necrosis factor alpha (TNF-α) antibody, is effective for the treatment o f active and fistulizing Crohn’s disease. Because infliximab is beneficial in p atients with Crohn’s disease, in whom other therapies have failed, it has been postulated that infliximab may also be helpful in patients with ulcerative colit is. Many investigators have studied the effectiveness of infliximab in ulcerativ e colitis, mainly in patients who are refractory to corticosteroids. Unfortunate ly, these studies have not yielded a conclusive answer to the efficacy of inflix imab in inducing remission in patients with severe ulcerative colitis. However, some have reported excellent results and others less effective, with the overall data being inconclusive. The purpose of this review is to summarize the current literature on the use of infliximab in ulcerative colitis, aswell as to provide insight into the possible mechanisms of why it may or may not work in these dif ficult-to-treat patients.